Abstract: A solid crystalline form of 1-(2-[4-(6-methoxy-3,4-dihydronaphthalene-1-y) phenoxy]ethyl)pyrrolidine, and a preparing process thereof are provided. The aforesaid compound is a key intermediate in the synthesis of lasofoxifene. A process for preparing lasofoxifene, a process for purifying lasofoxifene tartrate, and a crystalline form of lasofoxifene tartrate are also provided.
Type:
Grant
Filed:
April 27, 2010
Date of Patent:
January 20, 2015
Assignee:
Glenmark Generics Ltd.
Inventors:
Mubeen Ahmed Khan, Nikhil Rasiklal Trivedi, Nagan Nirmalan Kandasamy, Dayaghan Gangadhar Patil, Vipin Kumar Pandey, Sukumar Sinha
Abstract: Disclosed herein is a stable pharmaceutical composition comprising a substrate having deposited on its surface a layer comprising saxagliptin or pharmaceutically acceptable salts thereof, wherein a seal coat is not present between the substrate and the saxagliptin layer.
Type:
Application
Filed:
September 11, 2013
Publication date:
March 13, 2014
Applicant:
Glenmark Generics Ltd.
Inventors:
Atul Kaushik, Arra Ganga Srinivas, Kamal Mehta
Abstract: A process for the preparation of strontium ranelate or a hydrate thereof is provided comprising (a) reacting a tetraester compound of Formula II: wherein R, R1, R2, and R3 are independently a linear or branched C1-C6 alkyl group or a substituted or unsubstituted C3-C12 cyclic group, in the presence of a lithium base and in a solvent with an inorganic acid salt of strontium.
Abstract: The present invention provides an amorphous bupropion hydrobromide and an amorphous bupropion hydrobromide granulates with at least one pharmaceutically acceptable carrier, and a process for its preparation.
Type:
Grant
Filed:
June 15, 2009
Date of Patent:
May 28, 2013
Assignee:
Glenmark Generics Ltd.
Inventors:
Shankar Sanganabhatla, Vijay Soni, Mubeen Ahmed Khan, Nandlal Agarwal, Hemanth Kamble, Sharad Gore
Abstract: Processes for the purification of lercanidipine hydrochloride are provided which uses a binary system of an alcohol-containing solvent such as methanol and an aliphatic ester-containing solvent such as isopropyl acetate. Processes for the preparation of substantially amorphous lercanidipine hydrochloride are also provided. Also provided is lercanidipine hydrochloride substantially in polymorph form V.
Type:
Grant
Filed:
September 18, 2006
Date of Patent:
January 17, 2012
Assignee:
Glenmark Generics Ltd.
Inventors:
Mangesh Shivram Sawant, Maloyesh Mathuresh Biswas, Mubeen Ahmed Khan, Sukumar Sinha, Nitin Sharad Chandra Pradhan
Abstract: The present invention provides an amorphous bupropion hydrobromide and an amorphous bupropion hydrobromide granulates with at least one pharmaceutically acceptable carrier, and a process for its preparation.
Type:
Application
Filed:
June 15, 2009
Publication date:
May 5, 2011
Applicant:
Glenmark Generics Ltd.
Inventors:
Shankar Sanganabhatla, Vijay Soni, Mubeen Ahmed Khan, Nandlal Agarwal, Hemanth Kamble, Sharad Gore
Abstract: A substantially pure dextrorotatory isomer of zopiclone or a pharmaceutically acceptable salt thereof and crystalline forms thereof are provided. Also provided is a process for its preparation and pharmaceutical compositions containing same.
Abstract: A process for preparing 5H-dibenz[b,f]azepine-5-carboxamide of the general formula: wherein R1, R2, R3 and R4 are the same or different and can be hydrogen, halogen, nitro, cyano, carboxyl, R, —CO(R), —OCO(R), —O(R), —N(R)2, —CON(R)2, and —COO(R), wherein R is selected from the group consisting of C1-C10 alkyl, C3-C10 cycloalkyl, C2-C10 alkenyl, C5-C10 cycloalkenyl, C2-C10 alkynyl, and C6-C20 aryl, wherein the two A groups of —N(A)2 and —CON(A)2 can be the same or different, and wherein R2 and R3 can together form a bond is provided; the process comprising reacting 5H-dibenz[b,f]azepine of the general formula wherein R1, R2, R3 and R4 have the aforementioned meanings, with one or more alkali or alkaline-earth cyanates and in the presence of one or more unsaturated dicarboxylic acids.